GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » EV-to-FCF

SinoMab BioScience (HKSE:03681) EV-to-FCF : -8.64 (As of Jun. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SinoMab BioScience's Enterprise Value is HK$2,246.32 Mil. SinoMab BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-260.03 Mil. Therefore, SinoMab BioScience's EV-to-FCF for today is -8.64.

The historical rank and industry rank for SinoMab BioScience's EV-to-FCF or its related term are showing as below:

HKSE:03681' s EV-to-FCF Range Over the Past 10 Years
Min: -8.47   Med: -3.65   Max: -1.65
Current: -8.47

During the past 7 years, the highest EV-to-FCF of SinoMab BioScience was -1.65. The lowest was -8.47. And the median was -3.65.

HKSE:03681's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.31 vs HKSE:03681: -8.47

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), SinoMab BioScience's stock price is HK$1.76. SinoMab BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.262. Therefore, SinoMab BioScience's PE Ratio for today is At Loss.


SinoMab BioScience EV-to-FCF Historical Data

The historical data trend for SinoMab BioScience's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience EV-to-FCF Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -7.76 -12.90 -5.70 -4.00 -7.60

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.70 - -4.00 - -7.60

Competitive Comparison of SinoMab BioScience's EV-to-FCF

For the Biotechnology subindustry, SinoMab BioScience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's EV-to-FCF falls into.



SinoMab BioScience EV-to-FCF Calculation

SinoMab BioScience's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2246.315/-260.034
=-8.64

SinoMab BioScience's current Enterprise Value is HK$2,246.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-260.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SinoMab BioScience  (HKSE:03681) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SinoMab BioScience's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.76/-0.262
=At Loss

SinoMab BioScience's share price for today is HK$1.76.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SinoMab BioScience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.262.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


SinoMab BioScience EV-to-FCF Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience (HKSE:03681) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Liu Wenyi 2201 Interest of corporation controlled by you
Leung Shui On 2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience (HKSE:03681) Headlines

No Headlines